Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d12b35c0dd9adfb167b3b4f383afe93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_845dee65a3b9073bfd5dd429d700d189 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27c3980c665fca4652b322421eacff14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8563f33570305b21927a30b1a4b7b5b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2eb97d8c773024d2555452a42ae9d4d5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate |
2020-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_052cf47738ae216519f16db1eb75f912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c83cb890edde5de4fa893f6ad1e09cda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeee5e5c6dba6077333adb36dd2fed22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aa083465be8e68f6690ed0faf19d186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03d449586cbee351c778a3cffc85e338 |
publicationDate |
2022-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3945136-A1 |
titleOfInvention |
In vitro method for the prognosis of patients suffering from her2-positive breast cancer |
abstract |
The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer. |
priorityDate |
2020-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |